Annual Meeting Highlights

A Panel Discussion of Critical New Advances in Pancreatic Cancer from ASCO-GI to the 2019 ASCO Annual Meeting
A Panel Discussion of Critical New Advances in Pancreatic Cancer from ASCO-GI to the 2019 ASCO Annual Meeting
CME, CPE, CNE
Eileen M. O’Reilly, MD - Chairperson; Tanios Bekaii-Saab, MD, FACP; and Andrea Wang-Gillam, MD, PhD
Release Date: July 24, 2019
Expiration Date: July 24, 2020

Pancreatic cancer treatment options has shown slow progress in the past few years, however, recent studies suggest there may be new options on the horizon. Expert faculty will review some of the most relevant data from the 2019 ASCO-GI and 2019 ASCO Annual Meeting, and explain how this data may be clinically applicable in future practice. In this activity, Dr. Bekaii-Saab and Dr. Wang-Gillam will provide highlights from some of the select poster sessions. In addition, faculty will share data analysis from two very important trials presented at ASCO 2019. The first was presented as a Plenary Session this year looking at PARP inhibitors in the maintenance setting of pancreatic cancer in patients (POLO Trial) as well as APACT: A Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine for surgically resected pancreatic adenocarcinoma abstract data.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation, Ipsen, and Merck & Co., Inc.
Begin, Earn CreditView Only, No Credit
 
Annual Meeting Highlights of ASCO 2018 in Pancreatic Cancer
Annual Meeting Highlights of ASCO 2018 in Pancreatic Cancer
CME, CPE, CNE
J. Randolph Hecht, MD; Eileen M. O’Reilly, MD; Emanuel F. Petricoin III, PhD; Vincent Picozzi, Jr., MD, MMM; Federico A. Sanchez, MD; Andrea Wang-Gillam, MD, PhD
Release Date: July 19, 2018
Expiration Date: July 19, 2019
Although the mortality rate of pancreatic cancer is continuing to climb, recent advances in treatment options for the disease hold promise in improving patient outcomes. In this activity, participants will hear from leading experts in pancreatic cancer as they provide a review of key abstracts presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Participants can review summaries of clinical data, including commentary from investigators, on the significance of these studies and their impact on clinical practice. The presentations will provide an overview of investigational agents as well as first- and second-line combination therapies for patients with advanced/metastatic pancreatic cancer.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Ipsen, and Merck & Co., Inc.
View Only, CE ExpiredView Only, No Credit
 
2017 ESMO Meeting Highlights in Pancreatic Cancer
2017 ESMO Meeting Highlights in Pancreatic Cancer
CME, CPE
Andrea J. Bullock, MD, MPH; J. Randolph Hecht, MD; Philip A. Philip, MD, PhD, FRCP
Release Date: October 31, 2017
Expiration Date: October 31, 2018
Pancreatic cancer has now moved from the fourth leading cause of cancer-related death in the United States to the third, surpassing breast cancer. It is one of the few cancers where mortality is increasing, and most recent statistics show the 5-year overall survival rate for patients diagnosed with pancreatic cancer is just 8%. Although these statistics are illustrative of a poor prognosis, recent advances in pancreatic cancer treatment options hold promise in improving outcomes for patients.

In this activity, participants will hear from leading experts in pancreatic cancer as they provide a review of key abstracts presented this year at the European Society of Medical Oncology (ESMO) conference held in Madrid Spain.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
2017 ASCO Meeting Highlights in Pancreatic Cancer
2017 ASCO Meeting Highlights in Pancreatic Cancer
CME, CPE, CNE
Tanios Bekaii-Saab, MD, FACP; Alok A. Khorana, MD; Philip A. Philip, MD, PhD, FRCP, FABC; Ramesh Ramanathan, MD; Andrea Wang-Gillam, MD, PhD
Release Date: June 30, 2017
Expiration Date: June 30, 2018
This activity will describe eight clinically meaningful studies in pancreatic cancer that were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Participants will have the opportunity to review summaries of the clinical data, including commentary from investigators, regarding the significance of the data and its impact on practice. The presentations will provide an overview of investigational agents as well as combination therapies, in both the first-line and second-line, in the advanced/metastatic setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
2016 ASCO Meeting Highlights in Pancreatic Cancer
2016 ASCO Meeting Highlights in Pancreatic Cancer
CME, CPE
Kate O'Rourke
Release Date: June 30, 2016
Expiration Date: June 30, 2017
This activity will describe five exciting and clinically meaningful studies in pancreatic cancer that were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Participants will have the opportunity to review summaries of the clinical data, including commentary from investigators and authors, regarding the significance of the data and its impact on practice. The presentations address immuno-oncology, new agents, and novel combination therapies in both the first-line and advanced/metastatic setting for patients with pancreatic cancer.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of PartnersinPancreaticCancer.com.

©2020 MediCom Worldwide, Inc. All rights reserved